The American Joint Committee on Cancer/Union for International Cancer Control(AJCC/UICC)TNM(tumor node metastasis)classification for Nasopharyngeal carcinoma(NPC)is a valuable stool for evaluating tumor progression,gu...The American Joint Committee on Cancer/Union for International Cancer Control(AJCC/UICC)TNM(tumor node metastasis)classification for Nasopharyngeal carcinoma(NPC)is a valuable stool for evaluating tumor progression,guiding clinical treatment strategies as well as predicting prognosis.The 8th edition TNM classification(TNM-8)has notable limitations,such as overlapping prognosis between T2 and T3 categories as well as unbalanced distribution in the T and N classification and so on.The 9th edition TNM classification(TNM-9)was published in January this year and offered significant improvements over its predecessor,which provides more precise prognosis prediction and more appropriate clinical treatment guidance.A set of revisions were made in the TNM-9,containing upstaging N1-2 with advanced image-identified extranodal extension to N3 classification,subdividing M classification into M1a(≤3 metastatic lesions)and M1b(>3 metastatic lesions),and adjusting stage grouping.This commentary summarizes and evaluates the revisions in the TNM-9,and explores future research directions for further refinement of the staging system.展开更多
文摘The American Joint Committee on Cancer/Union for International Cancer Control(AJCC/UICC)TNM(tumor node metastasis)classification for Nasopharyngeal carcinoma(NPC)is a valuable stool for evaluating tumor progression,guiding clinical treatment strategies as well as predicting prognosis.The 8th edition TNM classification(TNM-8)has notable limitations,such as overlapping prognosis between T2 and T3 categories as well as unbalanced distribution in the T and N classification and so on.The 9th edition TNM classification(TNM-9)was published in January this year and offered significant improvements over its predecessor,which provides more precise prognosis prediction and more appropriate clinical treatment guidance.A set of revisions were made in the TNM-9,containing upstaging N1-2 with advanced image-identified extranodal extension to N3 classification,subdividing M classification into M1a(≤3 metastatic lesions)and M1b(>3 metastatic lesions),and adjusting stage grouping.This commentary summarizes and evaluates the revisions in the TNM-9,and explores future research directions for further refinement of the staging system.
